Saturday, October 12, 2019 2:39:39 PM
[color=red][/color]
- Q1/2019 - revenue of 22M
- Q2/2019 - revenue of 31.42M
- Q3/2019 - November 12, 2019
Pre market
- Capital Structure:
Fully diluted shares (as of May 10, 2019): 140M + ~potentially 15M from its latest bought deal.. So approximately ~155M
- Business model: wholesale(Private labelling + white labelling)/tolling
Sales/tolling agreements with - Supreme, Terrascend, Emerald Health, Indiva, JWCA, Cronos Group, Canopy Growth, & undisclosed licensed producer
More agreements to be announced
- Current capacity of 150,000kg - expected to complete expansion to 250,000kg by end of Q2/19 (hopefully to be announced soon this week)
- Cashed up
- has closed a credit agreement (the “Credit Facility”) with a top 5 Canadian Schedule 1 bank (the “Bank”) for an aggregate $38.7 million.
recently closed a $75M bought deal @$5.55 option to purchase additional shares up to $86M
Signed $20M in debt with schedule 1 Bank
Total cash $100M+
- Up list to TSX
- Global reach
Facility under construction in Australia (Expected to be completed in H2 2019) - 75,000 KG capacity expected for H2 2019 (November)
https://www.newcannabisventures.com/canadian-extraction-leader-medipharm-labs-announces-first-supply-partnerships-for-australian-subsidiary/
Facility in Australia will be the HUB to export extracts/finished products into Asia Pacific
Facility in Canada will be the HUB to export extracts/finished products into Europe
Awaiting EU GMP certification - expected H2 2019 ( in order to ship to the EU)
Recently completed its first export shipment into Australia to AusCann Group holdings (https://www.stockwatch.com/News/Item.aspx?bid=Z-C%3aLABS-2776284&symbol=LABS®ion=C) ;
- Building towards a pharmceutical company
Formed a Science Advisory Committee group;expert scientist, researchers, and medical professionals
Focused on Pharma-grade cannabis oil and concentrates
More information here: https://www.civilized.life/articles/how-medipharm-is-preparing-for-the-future-of-cannabis/ ;
- Slides:
https://d1io3yog0oux5.cloudfront.net/_0e3791d75c2e44476440cbd2788c3a11/medipharmlabs/db/357/2889/pdf/MediPharm+Labs+-+October+2019.pdf
https://stockdaymedia.com/cannabis/medipharm-labs-and-cronos-group-enter-private-label-contract-manufacturing-agreement/
https://m.benzinga.com/article/14480625?utm_referrer=https%3A%2F%2Fwww.google.com%2F&utm_source=https%3A%2F%2Fwww.google.com%2F
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM